Breast Clinical Trials
USOR #22101
EMBER-4: A randomized, open-label, Phase 3 study of adjuvant Imlunestrant vs standard adjuvant endocrine therapy in patients who have previously received 2 to 5 years of adjuvant endocrine therapy for ER+, HER2- early breast cancer with an increased risk of recurrence (J2J-MC-JZLH)